X-linked Hypophosphatemia Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02915705 -
Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
|
Phase 3 | |
| Recruiting |
NCT03879915 -
Dental Implants in Patients With X-linked Hypophosphatemia
|
||
| Active, not recruiting |
NCT03193476 -
Registry for Patients With X-Linked Hypophosphatemia
|
||
| Completed |
NCT05181839 -
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
|
||
| Completed |
NCT04146935 -
Examining the Effect of Burosumab on Muscle Function
|
Phase 4 | |
| Completed |
NCT02750618 -
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
| Active, not recruiting |
NCT03745521 -
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
|
||
| Completed |
NCT03920072 -
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
|
Phase 3 | |
| Recruiting |
NCT03748966 -
Calcitriol Monotherapy for X-Linked Hypophosphatemia
|
Early Phase 1 | |
| Recruiting |
NCT04419363 -
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
|
Phase 4 | |
| Completed |
NCT02163577 -
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
|
Phase 2 | |
| Active, not recruiting |
NCT03651505 -
X-linked Hypophosphatemia Disease Monitoring Program
|
||
| Completed |
NCT06067932 -
Foot Disorders in X-linked Hypophosphatemia
|
||
| Completed |
NCT04695860 -
Anti-FGF23 (Burosumab) in Adult Patients With XLH
|
Phase 3 | |
| Completed |
NCT02312687 -
Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
|
Phase 2 | |
| Completed |
NCT03596554 -
X-linked Hypophosphatemia and FGF21
|
||
| Recruiting |
NCT03820518 -
Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
|
Phase 4 | |
| Completed |
NCT01571596 -
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
|
Phase 1/Phase 2 | |
| Completed |
NCT04273490 -
Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
|
||
| Completed |
NCT03489993 -
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
|